According to the website of the National Medical Products Administration, the administration has recently approved the registration application for the tumor electric field therapy device of Hunan Antai Kangcheng Biotechnology Co., Ltd. This product consists of a host, junction box, disposable electrode pads, power adapter, lithium-ion battery, and charging dock. It generates a fixed frequency alternating electric field that acts on the brain and is suitable for patients aged 22 and above with newly diagnosed supratentorial glioblastoma through histopathology or imaging. After surgical treatment and radiation therapy, it can be used in combination with temozolomide (TMZ). This product is the first domestically produced product used for the treatment of this rare disease, and is expected to improve the accessibility of patient treatment. The drug regulatory authorities will strengthen post market supervision of the above-mentioned products to protect the safety of patients using medical devices. (New Society)